Emmessar Biotech & Nutrition Ltd

Key disclosures

• Unaudited standalone quarterly results for quarter ended 30 June 2026 approved by Board and Audit Committee.
• Limited Review Report on the quarter's results submitted by M/s. V. Nagarajan & Co.
• 34th AGM to be held via VC/OAVM on 29 September 2025; deemed venue is Registered Office.
• e-voting: cut-off date 22 September 2026; remote voting window 26–28 September 2026.
• Company operates two segments: Healthcare and Rent on Leasehold Land.
• No investor complaints received for quarter ended 30 June 2026.
• Results taken on record by Board and Audit Committee on 7 August 2026.
• Statement prepared under Ind AS 34; limited review; no material misstatement identified.

Dematerialisation processing and listing status

• Dematerialisation requests received during the quarter ended 30 June 2026 were confirmed to depositories.
• Securities dematerialised have been listed on the stock exchanges where the earlier issued securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled; depository's name substituted as registered owner within timelines.

""

Financial Performance

• Board approved unaudited financial results for quarter ended December 31, 2025.
• Limited review report by V Nagarajan & Co. found no material misstatements.

🗓️ Meeting Details

• Board meeting scheduled for February 11, 2026, in Mumbai.

📊 Financial Results

• Board to consider and approve unaudited financial results for quarter ended December 31, 2025.